|
WO2008058332A1
|
|
Diagnostic protocols for diabetes
|
|
WO2008028250A1
|
|
Therapeutic agents, targets and diagnostics
|
|
US2008146502A1
|
|
Methods for modulating the sensation of satiety perception and agents useful for same
|
|
MXPA06010108A
|
|
Diagnostic protocols.
|
|
US2011112167A1
|
|
Therapeutic agents and targets
|
|
CA2514071A1
|
|
Therapeutic molecules
|
|
CA2513300A1
|
|
Obesity-related genes
|
|
WO03033513A1
|
|
Differentially expressed genes associated with obesity and type 2 diabetes
|
|
WO03024206A1
|
|
Psammomys obesus as an animal model for behavioural conditions
|
|
EP1438407A1
|
|
Obesity related genes expressed at least in the hypotalamus, liver or pancreas
|
|
WO03016542A1
|
|
Obesity related genes expressed at least in the hypothalamus
|
|
AU2002344670B2
|
|
Modulating serum amyloid A interaction with tanis and agents useful for same
|
|
AU2002227795B2
|
|
Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
|
|
AUPR704201A0
|
|
A novel gene and uses therefor
|
|
AUPR589801A0
|
|
Modulation of physiological processes and agents useful for same
|
|
AUPR513701A0
|
|
A gene and uses therefor
|
|
WO0172320A1
|
|
A method of treatment of metabolic disorders and agents useful for same
|
|
AU4393801A
|
|
A method of treatment of metabolic disorders and agents useful for same
|
|
AUPR295001A0
|
|
A gene and uses therefor
|
|
AUPQ938500A0
|
|
A novel gene and uses therefor
|
